Expanding evidence for lower limb outcomes This systematic review and meta-analysis of randomized clinical trials and cohort studies found that GLP-1RA use was associated with a significantly lower risk of major limb events in people with type 2 diabetes and PAD
The real risk lies not in pharmacokinetics but in the combined physiological effect on blood glucose, gastrointestinal motility, and electrolyte balance
The clinical data showed 22.8% average weight loss at 48 weeks with 8 mg, which is comparable to the highest tirzepatide doses
Compared to traditional weight management clinics where you might wait weeks for an initial appointment and additional weeks for insurance authorization, that timeline is remarkably fast
Further increases to 1.0mg, 1.7mg, and potentially 2.4mg happen at four-week intervals based on tolerance and response
January 2026: Strong pipeline activity was observed in oral anti-diabetic drugs, with increased focus on SGLT2 inhibitors and combination therapies aimed at reducing cardiovascular risks in diabetic patients
